Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1600 1635 1637 1654 1682 4100
This examiner grants 49% of resolved cases
Keyur Anilkumar Vyas works in Tech Center 4100 and Art Unit 1600. The examiner has 77 resolved cases. The allowance rate is 49.4 percent. This indicates a more challenging environment for applicants, as less than a majority of resolved cases result in a grant. Practitioners should be prepared for a detailed examination process when assigned to this examiner.
The interview lift is 60.8 percent. This significant lift suggests that interviews are a very effective way to improve the 49.4 percent allowance rate. Practitioners should prioritize interviews to advance their applications and resolve outstanding issues. The data indicates that direct communication in Art Unit 1600 is a powerful tool for overcoming rejections and reaching a grant.
The median days to allowance is 1349. This timeline is relatively long, reflecting the typical pendency for successful applications. With 77 resolved cases, the data provides a clear picture of the examiner's performance in Tech Center 4100. This timeframe is an important factor for applicants to consider when planning their patent strategy.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17821806 | Treatment Of Inflammatory Diseases With RAS Protein Activator Like 3 (RASAL3) Inhibitors | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17078627 | METHODS FOR TREATING PARKINSON'S DISEASE | Final Rejection | Korea Advanced Institute of Science and Technology |
| 18501859 | Methods and Compositions for Treating, Ameliorating, and/or Preventing Chronic Kidney Disease (CKD) and Complications thereof by Regulating DPEP1, CASP9, ACSS2 and/or FASN | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17047967 | MITOCHONDRIAL RNA IMPORT FOR TREATING MITOCHONDRIAL DISEASE | Final Rejection | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 18581511 | BETA-CATENIN (CTNNB1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 17773508 | COMPOSITIONS AND METHODS FOR SILENCING DNAJB1-PRKACA FUSION GENE EXPRESSION | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 17260732 | TREATMENT OF MUCOPOLYSACCHARIDOSIS I WITH FULLY-HUMAN GLYCOSYLATED HUMAN ALPHA-L-IDURONIDASE (IDUA) | Non-Final OA | REGENXBIO RS LLC |
| 17055061 | SUBSTITUTION OF THE MESSENGER RNA CAP WITH TWO RNA SEQUENCES INTRODUCED AT THE 5-PRIME END THEREOF | Final Rejection | MESSENGER BIOPHARMA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy